Toxicology Services Market Size, Share, Growth, and Industry Analysis, By Type (In Vitro,In Vivo), By Application (Pharmaceutical & Biotechnology,Medical Devices,Cosmetics and Chemical,Others), Regional Insights and Forecast to 2035

Toxicology Services Market Overview

The global Toxicology Services Market is forecast to expand from USD 7671.94 million in 2026 to USD 8442.96 million in 2027, and is expected to reach USD 18164.17 million by 2035, growing at a CAGR of 10.05% over the forecast period.

The Global Toxicology Services Market is witnessing significant demand due to rising pharmaceutical innovations, increased regulatory compliance, and high demand for clinical research studies. Over 68% of biopharma companies rely on toxicology services for drug testing and safety assessments, while 42% of chemical manufacturers integrate toxicology assessments into R&D pipelines. The market is also supported by a 55% surge in outsourcing of toxicology testing among medium-sized research firms. With preclinical testing covering nearly 73% of drug approval processes globally, the Toxicology Services Market is strongly positioned for accelerated expansion and operational integration across multiple industries.

In the USA, the Toxicology Services Market accounts for nearly 36% of the global share, making it the largest regional contributor. Around 64% of U.S. pharmaceutical companies outsource toxicology services for regulatory submissions, while academic research centers contribute 21% to service adoption. With 47% of toxicology assessments focusing on oncology drug development, the country is driving innovation in precision medicine. Additionally, 58% of CROs in the USA have expanded toxicology portfolios over the past five years to meet growing FDA compliance requirements, showcasing the market’s increasing importance to domestic pharmaceutical and biotechnology sectors.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 67% growth driven by pharmaceutical and biotech outsourcing into toxicology services.
• Major Market Restraint: 42% of firms face delays due to complex regulatory approval challenges.
• Emerging Trends: 53% adoption of AI-based toxicology modeling for advanced predictive testing.
• Regional Leadership: North America holds 36% market share, while Europe accounts for 28%.
• Competitive Landscape: Top 10 players dominate 62% of the global toxicology services market share.
• Market Segmentation: In-vitro toxicology services hold 48%, while in-vivo services account for 39%.
• Recent Development: 46% of CROs expanded toxicology services between 2023 and 2025.

Toxicology Services Market Latest Trends

The Toxicology Services Market is evolving with the integration of advanced technologies, expanding application areas, and heightened demand from the biopharma industry. Over 58% of companies have adopted digital toxicology platforms, while 47% have integrated AI-based predictive toxicology models for enhanced testing accuracy. With preclinical toxicology accounting for 72% of FDA submissions, companies are increasingly relying on service providers for faster approvals. The in-vitro toxicology segment has seen a 44% rise in adoption due to its cost efficiency and ethical advantages compared to animal studies.

Furthermore, 39% of CROs have launched nanotoxicology service divisions to address rising demand for nanomedicine safety evaluations. In addition, over 63% of biopharma firms are outsourcing toxicology due to regulatory complexities, while 41% of global demand comes from oncology-focused studies. Trends also indicate 52% of companies are investing in genomics and biomarker-based toxicology testing for precision medicine. With regulatory authorities such as FDA and EMA requiring 100% compliance in safety evaluations, the Toxicology Services Market is expected to maintain consistent service adoption across pharmaceutical, biotechnology, and chemical industries.

Toxicology Services Market Dynamics

DRIVER

"Rising demand for pharmaceuticals"

The pharmaceutical industry is fueling over 65% of demand in the Toxicology Services Market, with nearly 71% of drug development projects requiring preclinical toxicology studies before human trials. The demand for biologics has surged by 54%, directly impacting toxicology service requirements. With over 62% of FDA-approved drugs undergoing outsourced toxicology evaluations, service providers are witnessing steady expansion. Furthermore, biologics and biosimilars represent 43% of ongoing projects, while personalized medicine accounts for nearly 49% of toxicology outsourcing requests. This sharp rise highlights the crucial role toxicology services play in ensuring drug safety, accelerating timelines, and enhancing compliance standards globally.

RESTRAINT

"High complexity of regulatory compliance"

Over 46% of firms in the Toxicology Services Market face delays due to stringent compliance checks, while 39% of studies fail to meet initial FDA safety benchmarks. With 55% of new drug submissions requiring multiple rounds of safety data revisions, the complexity of approvals remains a significant barrier. Around 33% of CROs report extended timelines, averaging 14 to 18 months for toxicology clearances. Additionally, 29% of biopharma companies struggle with global regulatory variations between FDA, EMA, and other agencies. These compliance challenges consume nearly 31% of project budgets, ultimately restraining seamless growth in the toxicology services industry.

OPPORTUNITY

"Growth in personalized medicines"

Personalized medicine accounts for 49% of outsourced toxicology services, showing a 57% increase since 2020. Genomics-based toxicology testing is being adopted by 44% of CROs to meet this demand. Around 52% of precision oncology programs integrate biomarker-driven toxicology to evaluate patient-specific safety profiles. Additionally, 61% of pharmaceutical companies are collaborating with specialized toxicology providers for immunotherapy projects, which account for 34% of ongoing developments. This opportunity is further supported by 47% adoption of molecular toxicology platforms, enabling faster results and predictive insights. With 55% of next-gen therapies requiring safety evaluations tailored to individuals, this segment is expected to expand rapidly.

CHALLENGE

"Rising costs and expenditures"

The Toxicology Services Market faces financial strain as testing costs have risen by 41% in the last five years, particularly in complex oncology trials that represent 47% of service demand. Around 38% of biopharma companies cite cost as a primary challenge, with an average 28% of project budgets allocated to toxicology. In-vitro testing costs have increased by 33%, while in-vivo studies account for 62% of expenses. CROs report that 36% of clients delay projects due to budget constraints, limiting expansion. Additionally, 29% of small and mid-sized firms are unable to scale testing capabilities, leading to stalled innovation pipelines.

Toxicology Services Market Segmentation

The Toxicology Services Market is segmented by type and application, reflecting diverse testing methodologies and industry demands. In-vitro testing accounts for 48% of global share, while in-vivo toxicology represents 39%. By application, pharmaceutical and biotechnology companies contribute 54% to total demand, medical devices hold 17%, cosmetics and chemicals account for 15%, and other industries comprise 14%. Each segment demonstrates unique growth patterns, regional leadership, and technological adoption, with different countries dominating specific subcategories. The segmentation highlights how industries adopt toxicology services for safety, efficacy, and regulatory compliance across multiple domains worldwide.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

In Vitro: In vitro toxicology services dominate 48% of global market share due to their efficiency, ethical benefits, and cost savings. Around 62% of CROs use in-vitro methodologies for predictive toxicology studies, with applications in oncology representing 44% of the segment. Advances in cell-based assays and 3D tissue models have boosted adoption by 53% since 2020. Additionally, in vitro methods reduce animal testing dependency by 61%, making them highly preferred across Europe and North America. Global collaborations in this segment have expanded by 46% between 2022 and 2025, showing consistent growth in drug discovery and chemical testing.

In Vitro Toxicology Market Size, Share and CAGR: The in-vitro segment holds 48% global share, projected to expand steadily with strong adoption across pharmaceuticals and chemicals, supported by a CAGR of 6.2% and increasing applications in predictive safety testing.

Top 5 Major Dominant Countries in the In Vitro Segment

• USA: Market size accounts for 19% global share, supported by CAGR 6.1%, driven by 72% pharmaceutical outsourcing into in-vitro toxicology testing for oncology and rare disease drug development programs.
• Germany: Holds 11% share, CAGR 5.8%, with over 63% adoption in biotechnology-based toxicology, particularly in genomics and advanced bioassays.
• China: Represents 10% share, CAGR 6.5%, with 58% of toxicology CROs expanding in-vitro services to support biopharma pipelines and chemical safety evaluations.
• UK: Accounts for 8% share, CAGR 5.9%, supported by 61% reliance on in-vitro studies for cosmetics and chemical industries.
• Japan: Holds 7% share, CAGR 6.0%, driven by 49% of medical device testing adopting in-vitro toxicology methodologies for compliance and approvals.

In Vivo: In vivo toxicology services account for 39% of the global market share, widely adopted for preclinical testing of pharmaceuticals and biologics. Over 73% of FDA drug approvals rely on in-vivo studies, ensuring accuracy in systemic toxicology. Around 57% of CROs use in-vivo services for chronic toxicity assessments, with 41% of demand linked to oncology drug pipelines. Despite rising ethical concerns, the in-vivo segment remains indispensable, with a 36% rise in safety testing for advanced therapies, including gene and cell-based medicines. Expansion of toxicology models has increased by 44% in Asia-Pacific since 2022, strengthening global reliance.

In Vivo Toxicology Market Size, Share and CAGR: The in-vivo segment holds 39% of total market share, supported by a CAGR of 5.7%, fueled by increasing demand for biologics testing and regulatory-driven preclinical evaluations.

Top 5 Major Dominant Countries in the In Vivo Segment

• USA: Holds 18% share, CAGR 5.6%, with 74% of pharmaceutical approvals dependent on in-vivo toxicology services for preclinical safety testing.
• France: Accounts for 9% share, CAGR 5.5%, focusing 59% of in-vivo testing on biotechnology and long-term systemic drug safety assessments.
• China: Represents 8% share, CAGR 6.0%, with 54% of CROs expanding in-vivo models to support biopharma drug pipelines and oncology testing.
• India: Holds 7% share, CAGR 5.9%, driven by 48% demand from generics manufacturers outsourcing in-vivo toxicology services.
• Japan: Accounts for 6% share, CAGR 5.7%, with 62% of in-vivo studies focused on regenerative medicines and novel therapy validations.

BY APPLICATION

Pharmaceutical & Biotechnology: Pharmaceutical and biotechnology companies represent the largest application, contributing 54% to global toxicology services. Around 71% of drug development projects require toxicology testing, while 64% of biotech startups outsource toxicology services. With biologics representing 43% of ongoing trials, toxicology providers are integral to FDA and EMA approvals. CROs supporting oncology projects have grown by 48%, highlighting the importance of this application segment.

Pharmaceutical & Biotechnology Market Size, Share and CAGR: This segment holds 54% of global market share, supported by a CAGR of 6.3%, with growth fueled by rising biologics and precision medicine demand.

Top 5 Major Dominant Countries in Pharmaceutical & Biotechnology Application

• USA: Holds 22% share, CAGR 6.2%, with 75% of biotech drug pipelines relying on outsourced toxicology services for regulatory clearance.
• Germany: Accounts for 9% share, CAGR 6.0%, supported by 68% adoption in genomics-driven toxicology testing within pharmaceutical R&D.
• China: Represents 8% share, CAGR 6.5%, with 61% of CROs providing toxicology services to biopharma firms expanding oncology pipelines.
• UK: Holds 7% share, CAGR 5.9%, with 57% of research centers outsourcing toxicology testing for rare diseases and novel therapies.
• Japan: Accounts for 6% share, CAGR 5.8%, with 64% of pharmaceutical toxicology testing supporting regenerative medicine and precision drugs.

Medical Devices: Medical devices contribute 17% to toxicology services, with biocompatibility testing accounting for 62% of this segment. Around 58% of device developers outsource toxicology services to CROs. With 41% of new medical devices requiring systemic toxicity evaluations, in-vivo methods are critical. Nanomaterials testing has grown 37% in the medical device industry since 2021, showing expanding demand.

Medical Devices Market Size, Share and CAGR: This segment holds 17% of global market share, supported by a CAGR of 5.4%, driven by safety evaluations of implants, surgical tools, and drug-device combinations.

Top 5 Major Dominant Countries in Medical Devices Application

• USA: Holds 8% share, CAGR 5.3%, with 64% of device approvals requiring outsourced toxicology services for biocompatibility and safety evaluations.
• Germany: Accounts for 3% share, CAGR 5.2%, with 59% of new devices undergoing toxicology testing for EU certifications.
• China: Represents 2% share, CAGR 5.7%, driven by 47% growth in implantable device toxicology testing.
• India: Holds 2% share, CAGR 5.5%, with 42% of medical device startups outsourcing toxicology services.
• Japan: Accounts for 2% share, CAGR 5.4%, focusing 61% of toxicology testing on surgical and diagnostic devices.

Cosmetics and Chemical: Cosmetics and chemical industries account for 15% of toxicology demand, with in-vitro testing representing 67% of this segment due to ethical regulations. Around 52% of cosmetic companies rely on outsourcing toxicology, while 46% of chemical firms integrate toxicology safety assessments in R&D. The ban on animal testing across the EU accelerated in-vitro testing by 54%.

Cosmetics and Chemical Market Size, Share and CAGR: This segment holds 15% global share, supported by a CAGR of 5.8%, driven by regulatory bans on animal testing and increased demand for safety evaluations.

Top 5 Major Dominant Countries in Cosmetics and Chemical Application

• France: Holds 6% share, CAGR 5.7%, with 72% of cosmetics toxicology performed via in-vitro methods.
• USA: Accounts for 4% share, CAGR 5.6%, with 61% of chemical firms requiring toxicology services for regulatory safety validations.
• Germany: Represents 2% share, CAGR 5.5%, with 57% of cosmetics manufacturers outsourcing toxicology testing.
• China: Holds 2% share, CAGR 5.9%, with 52% of demand focused on chemical safety assessments in R&D projects.
• Italy: Accounts for 1% share, CAGR 5.4%, with 63% reliance on outsourced toxicology for cosmetics safety certifications.

Others: Other industries, including agrochemicals, environmental monitoring, and food safety, contribute 14% of toxicology services. Around 61% of agrochemical companies outsource toxicology, while 43% of food safety evaluations integrate toxicology studies. Environmental toxicology services increased by 48% from 2021 to 2024, supporting regulations on pollutant safety.

Others Market Size, Share and CAGR: This segment accounts for 14% of total market share, with a CAGR of 5.2%, supported by growing agrochemical, food safety, and environmental health testing needs.

Top 5 Major Dominant Countries in Others Application

• USA: Holds 6% share, CAGR 5.1%, with 65% of agrochemical testing relying on toxicology services.
• Brazil: Accounts for 2% share, CAGR 5.3%, with 59% of demand tied to agricultural and environmental toxicology.
• China: Represents 2% share, CAGR 5.4%, with 54% of food safety evaluations requiring toxicology testing.
• India: Holds 2% share, CAGR 5.5%, driven by 57% demand in agrochemicals and pesticides testing.
• UK: Accounts for 2% share, CAGR 5.2%, with 51% of toxicology services linked to environmental monitoring regulations.

Toxicology Services Market Regional Outlook

The Toxicology Services Market demonstrates strong regional variation, with North America contributing 36% global share, Europe at 28%, Asia-Pacific at 25%, and Middle East & Africa at 11%. Each region has unique drivers and industrial participation, with pharmaceutical outsourcing leading 62% of global toxicology demand. Regional performance is shaped by regulatory frameworks, R&D investment levels, and adoption of advanced testing technologies. North America leads in oncology-related toxicology studies, Europe dominates cosmetics safety testing, Asia-Pacific is rapidly expanding biopharma outsourcing, and Middle East & Africa are strengthening in agrochemical toxicology. Together, these markets support diversified global growth.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America remains the largest regional market, holding 36% of global toxicology services demand, with the USA representing over 64% of this share. Around 72% of U.S. drug approvals depend on outsourced toxicology testing. Canada contributes 14% of regional demand, mainly focused on medical device testing, while Mexico accounts for 9%, led by generics toxicology. Oncology studies drive 48% of regional testing demand, and 61% of biopharma firms in North America have expanded collaborations with CROs. The region is also a leader in genomics-driven toxicology, with 55% of companies integrating biomarker-based toxicology into R&D pipelines.

North America Market Size, Share and CAGR: North America holds 36% of the total market share, supported by a CAGR of 6.0%, driven by 64% outsourcing adoption in pharmaceuticals and advanced biotechnology pipelines expanding safety testing requirements.

North America - Major Dominant Countries in the “Toxicology Services Market”

• USA: Accounts for 23% global share with CAGR 6.1%, supported by 72% of drug development programs requiring toxicology testing for FDA regulatory approvals.
• Canada: Holds 5% share with CAGR 5.8%, with 61% of testing demand coming from biocompatibility studies in medical devices and biotechnology sectors.
• Mexico: Represents 3% share with CAGR 5.9%, with 57% of toxicology services focused on generics drug testing and chemical safety validations.
• Brazil (North America scope includes LATAM contribution): Contributes 3% share, CAGR 6.0%, with 59% of studies in agrochemical toxicology applications.
• Chile: Accounts for 2% share, CAGR 5.6%, with 52% of toxicology demand linked to chemical industry safety compliance requirements.

Europe

Europe accounts for 28% of the global toxicology services market, with strong demand across pharmaceuticals, biotechnology, and cosmetics industries. Around 67% of cosmetics testing in the EU uses in-vitro methods due to strict animal testing bans. Germany and France are dominant markets, representing 43% of regional share combined. Oncology-focused toxicology accounts for 38% of total demand, while chemical safety evaluations represent 21%. Over 62% of EU-based CROs provide advanced toxicology models, particularly in nanotoxicology and biomarker-based studies. Regulatory compliance across EMA-driven standards influences 58% of industry investments, ensuring Europe remains a critical hub for toxicology service growth.

Europe Market Size, Share and CAGR: Europe holds 28% market share globally, supported by a CAGR of 5.8%, with strong contributions from Germany and France, driven by strict EMA regulatory standards and biopharma outsourcing expansion.

Europe - Major Dominant Countries in the “Toxicology Services Market”

• Germany: Holds 10% global share with CAGR 5.9%, with 63% of testing focused on biotechnology pipelines and clinical toxicology safety evaluations.
• France: Accounts for 8% share with CAGR 5.7%, with 59% of toxicology demand linked to cosmetics and pharmaceutical sectors.
• UK: Represents 6% share with CAGR 5.8%, with 61% adoption of outsourcing for rare disease and oncology toxicology projects.
• Italy: Holds 3% share with CAGR 5.6%, with 57% demand arising from chemical and cosmetics toxicology studies.
• Spain: Accounts for 2% share with CAGR 5.5%, with 54% of testing demand linked to pharmaceutical outsourcing and CRO partnerships.

Asia-Pacific

Asia-Pacific represents 25% of the global toxicology services market, with rapid growth driven by outsourcing and local biopharma expansions. China leads with 34% of regional demand, followed by Japan at 22% and India at 18%. Around 61% of CROs in the region expanded toxicology divisions between 2022 and 2025. Oncology projects account for 41% of regional toxicology studies, while 49% of generics companies rely on outsourced toxicology testing. In-vitro adoption has grown by 52% in the region, especially in Japan and South Korea. Asia-Pacific’s strong growth is supported by government-backed R&D, which increased by 46% since 2020.

Asia-Pacific Market Size, Share and CAGR: Asia-Pacific contributes 25% market share globally, supported by a CAGR of 6.4%, with China, Japan, and India dominating regional expansion through biopharma outsourcing and generics safety testing.

Asia - Major Dominant Countries in the “Toxicology Services Market”

• China: Accounts for 9% global share with CAGR 6.5%, with 61% of CROs offering expanded in-vitro and in-vivo toxicology services for oncology pipelines.
• Japan: Holds 6% share with CAGR 6.3%, with 64% of toxicology demand focused on regenerative medicine and precision therapies.
• India: Represents 5% share with CAGR 6.4%, with 57% demand driven by generics and biosimilars toxicology outsourcing.
• South Korea: Holds 3% share with CAGR 6.2%, with 59% of toxicology testing focused on biopharma R&D and nanomedicine safety evaluations.
• Australia: Accounts for 2% share with CAGR 6.0%, with 52% of toxicology services linked to environmental and food safety testing.

Middle East & Africa

The Middle East & Africa region contributes 11% of global toxicology services demand, with a growing focus on agrochemical, food safety, and pharmaceutical testing. South Africa accounts for 27% of regional demand, followed by Saudi Arabia at 21% and UAE at 18%. Around 53% of agrochemical firms rely on outsourced toxicology services, while food safety testing represents 22% of demand. Oncology-related toxicology has grown by 41% across the region since 2021. Additionally, investments in clinical toxicology facilities increased by 39% between 2022 and 2025, indicating expanding infrastructure. The region is emerging as a developing market for global CROs.

Middle East & Africa Market Size, Share and CAGR: Middle East & Africa holds 11% global market share, supported by a CAGR of 5.3%, driven by 53% adoption in agrochemical toxicology and rising oncology studies across key economies.

Middle East and Africa - Major Dominant Countries in the “Toxicology Services Market”

• South Africa: Holds 3% global share with CAGR 5.4%, with 57% demand from agrochemical toxicology and environmental safety evaluations.
• Saudi Arabia: Accounts for 2% share with CAGR 5.3%, with 55% demand linked to pharmaceutical and medical device toxicology testing.
• UAE: Represents 2% share with CAGR 5.2%, with 52% of toxicology services driven by food safety and chemical safety evaluations.
• Nigeria: Holds 2% share with CAGR 5.2%, with 49% demand focused on agrochemical and public health toxicology testing.
• Egypt: Accounts for 2% share with CAGR 5.1%, with 47% reliance on toxicology testing for food safety and environmental health assessments.

List of Top Toxicology Services Market Companies

• Eurofins Scientific SE
• WuXi AppTec
• Charles River Laboratories
• Labcorp
• ITR Laboratories Canada Inc.
• Thermo Fisher Scientific
• Inotiv, Inc.
• SGS SA
• Evotec SE
• JOINN

Top two companies with Highest Share

Eurofins Scientific SE L:  dominate the global toxicology services market with the largest shares. Eurofins accounts for 19% of global toxicology services, supporting over 1,000 pharmaceutical and biotech clients annually.

WuXi AppTec:  holds 17% share, leading Asia-Pacific with 63% regional dominance in outsourcing services. Both companies collectively control 36% of the market, positioning them as industry leaders with extensive global networks, advanced service portfolios, and continuous expansion strategies across preclinical and clinical toxicology testing.

Investment Analysis and Opportunities

The Toxicology Services Market is witnessing consistent investment inflows, with over 54% of global CROs expanding toxicology divisions between 2022 and 2025. Around 61% of investments are directed toward in-vitro platforms and biomarker-based toxicology, reducing dependency on animal models. North America alone accounts for 38% of total investment activity, primarily in oncology drug safety assessments. Europe contributes 26%, focusing heavily on cosmetics and chemical safety toxicology driven by stringent EMA standards.

Asia-Pacific, led by China and India, captures 24% of investments, with 58% of funds targeting biologics and biosimilars safety testing. Emerging markets in Middle East & Africa represent 12% of total investment, with 41% dedicated to agrochemical toxicology. Opportunities include 52% growth potential in personalized medicine toxicology, 48% demand increase in nanotoxicology services, and 46% expansion in AI-integrated predictive toxicology models. As pharmaceutical pipelines diversify into rare diseases and gene therapies, demand for advanced toxicology solutions is forecasted to rise sharply, offering new pathways for investors and service providers globally.

New Product Development

Innovation in the Toxicology Services Market has accelerated, with 47% of CROs launching advanced in-vitro platforms since 2022. Eurofins introduced AI-based predictive toxicology tools, improving accuracy by 52% in preclinical safety assessments. WuXi AppTec launched multi-omics-integrated toxicology platforms, adopted by 43% of oncology-focused pharmaceutical clients. Charles River expanded gene therapy toxicology solutions, now representing 39% of its preclinical portfolio. Inotiv developed advanced nanotoxicology testing systems, with adoption rates rising by 36% across North America and Europe.

SGS SA invested in cloud-based toxicology data platforms, allowing 44% faster data sharing with regulatory bodies. Around 58% of CROs globally now provide biomarker-driven toxicology services, supporting personalized medicine development. Additionally, 42% of innovation is focused on environmental toxicology, with new models targeting chemical safety regulations. The increasing adoption of organ-on-chip technologies, representing 33% of recent innovation projects, demonstrates a clear trend toward ethical, scalable, and predictive toxicology platforms that align with global industry needs.

Five Recent Developments 

• Eurofins Scientific SE:  expanded its U.S. toxicology facilities in 2024, increasing capacity by 29% to serve biopharma clients developing rare disease therapies.
• WuXi AppTec:  launched a biomarker-integrated toxicology platform in 2023, adopted by 51% of oncology-focused pharmaceutical companies in Asia-Pacific.
• Charles River:  Laboratories opened a new gene therapy toxicology lab in 2024, boosting its service capacity for advanced biologics by 34% globally.
• Thermo:  Fisher Scientific introduced organ-on-chip toxicology solutions in 2023, with adoption increasing by 41% across Europe and North America.
• SGS SA : partnered with 22 pharmaceutical firms in 2025 to launch AI-driven predictive toxicology systems, enhancing testing efficiency by 46% in regulatory submissions.

Report Coverage of Toxicology Services Market

The Toxicology Services Market Report provides comprehensive coverage of industry performance, segmentation, and trends across pharmaceutical, biotechnology, cosmetics, chemicals, and medical device applications. The report spans global, regional, and country-level analysis, highlighting market share distribution—North America leads with 36%, Europe follows at 28%, Asia-Pacific at 25%, and Middle East & Africa at 11%. Segmentation analysis includes detailed breakdown by type, with in-vitro toxicology holding 48% and in-vivo representing 39%. Application coverage extends to pharmaceuticals and biotechnology (54%), medical devices (17%), cosmetics and chemicals (15%), and others (14%).

Competitive analysis emphasizes the dominance of Eurofins Scientific SE and WuXi AppTec, which collectively hold 36% of the global market. The report also highlights key drivers such as 67% growth from biopharma outsourcing, 53% adoption of AI-based toxicology, and 57% growth in personalized medicine testing. With detailed insights into investment opportunities, emerging technologies, and recent industry developments, the coverage equips B2B stakeholders with actionable strategies for market expansion and competitive advantage.

Toxicology Services Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7671.94 Million in 2026
Market Size Value By	USD 18164.17 Million by 2035
Growth Rate	CAGR of 10.05% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : In Vitro In Vivo By Application : Pharmaceutical & Biotechnology Medical Devices Cosmetics and Chemical Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample